# DefiniGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/definigen

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.definigen.com
- Total disclosed funding: $12M
- Latest round: Series A (Nov 19, 2020)
- Investors on record: 10

## About

Established in 2012 and based in the UK, DefiniGEN Limited operates as a biotechnology company that develops in providing disease model human cells, including hepatocytes, pancreatic beta cells, and intestinal organoids.

## Funding rounds

- Series A, Nov 19, 2020, $4.3M — BGF Investment Management, 24Haymarket
- Series B, Apr 5, 2016, $2.2M — Cambridge Enterprise, Cambridge Capital Group, Cambridge Angels Group, Parkwalk Advisors, 24Haymarket, Providence Investment Company
- Series A, Jun 2, 2014, $3.8M — Cambridge Enterprise, Cambridge Capital Group, London Business Angels, Wren Capital, 24Haymarket, Ranworth Capital, Providence Investment Company
- Series A, Dec 20, 2013, $2.1M — Cambridge Enterprise, 24Haymarket

## Investors

- Cambridge Enterprise — Series A, Series B
- 24Haymarket (https://capitalatlas.ai/funds/24haymarket) — Series A, Series B
- Cambridge Capital Group — Series A, Series B
- London Business Angels — Series A
- Wren Capital (https://capitalatlas.ai/funds/wren-capital) — Series A
- Ranworth Capital (https://capitalatlas.ai/funds/ranworth-capital) — Series A
- Providence Investment Company — Series A, Series B
- Cambridge Angels Group — Series B
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series B
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series A